Version history

{
  "description": "## Mechanistic Overview\nTREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"## **Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) signaling cascade represents a critical node in neuroinflammation regulation, with its dysfunction fundamentally altering astrocyte-microglia communication networks. TREM2 functions as a transmembrane glycoprotein exclusively expressed on microglia within the central nervous system, forming a signaling complex with the adaptor protein TYROBP (also known as DAP12). Upon ligand engagement, TREM2 undergoes conformational changes that activate TYROBP's immunoreceptor tyrosine-based activation motifs (ITAMs), initiating a phosphorylation cascade involving Syk kinase, PI3K/Akt, and mTOR pathways. The molecular basis of astrocyte-microglia cross-talk begins when TREM2 recognizes diverse ligands including phosphatidylserine on apoptotic cells, amyloid-β oligomers, tau aggregates, and apolipoprotein E. This recognition triggers rapid microglial activation characterized by calcium mobilization through PLCγ2-mediated IP3 production and subsequent release of specific signaling molecules. Key intercellular mediators include IL-33, which binds astrocytic ST2 receptors to induce neuroprotective gene expression; TNF-α, which activates astrocytic NF-κB signaling; and ATP, which engages P2Y1 and P2X7 receptors on astrocytes to modulate calcium dynamics and inflammatory responses. Under physiological TREM2 signaling, activated microglia release lactate and glutamate that serve as metabolic substrates for astrocytes while simultaneously triggering astrocytic production of glutamine synthetase and brain-derived neurotrophic factor (BDNF). This metabolic coupling ensures adequate energy supply to neurons during stress conditions. Additionally, TREM2-activated microglia secrete complement regulatory proteins including clusterin and vitronectin, which coordinate with astrocytic complement inhibitors C3aR and C5aR to prevent excessive synaptic pruning. The communication network extends to chemokine signaling, where microglial CCL2 and CX3CL1 production modulates astrocytic migration and morphological changes through CCR2 and CX3CR1 receptors respectively. ## **Preclinical Evidence** Extensive preclinical studies utilizing TREM2 knockout models have revealed profound disruptions in astrocyte-microglia communication with quantifiable impacts on neurodegeneration. In 5xFAD mice lacking TREM2, researchers observed a 45-65% reduction in microglial clustering around amyloid plaques compared to wild-type controls, accompanied by significantly altered astrocytic morphology and gene expression profiles. Single-cell RNA sequencing studies demonstrated that TREM2-deficient microglia exhibit reduced expression of communication molecules including Il33 (decreased 70%), Tnfa (decreased 55%), and lactate dehydrogenase genes, correlating with diminished astrocytic activation markers such as Gfap, S100b, and complement regulatory genes. Functional studies in primary microglial-astrocyte co-cultures revealed that conditioned medium from TREM2-knockout microglia failed to induce protective astrocytic responses, with 40-60% reduced production of neuroprotective factors including TGF-β, IL-10, and glutamine synthetase compared to wild-type microglial supernatants. Conversely, direct TREM2 activation using specific agonists increased astrocytic BDNF production by 3-fold and enhanced complement inhibitor expression by 2.5-fold within 6 hours of treatment. In vivo calcium imaging studies using two-photon microscopy in awake behaving mice demonstrated that TREM2-deficient animals showed disrupted coordinated calcium responses between microglia and astrocytes during acute brain injury, with temporal correlation coefficients reduced from 0.72 in controls to 0.34 in knockouts. Electrophysiological recordings revealed that TREM2 loss resulted in 35% increased synaptic pruning rates and 50% reduced long-term potentiation in hippocampal slices, effects that could be rescued by co-culturing with wild-type astrocytes but not wild-type microglia alone. Tau propagation studies in P301S mice crossed with TREM2 knockouts showed accelerated pathology spread with 80% increased tau phosphorylation in projection areas, accompanied by reduced astrocytic barrier formation around tau aggregates. Metabolomic analyses revealed disrupted lactate-glutamine cycling between glia, with 60% reduced lactate transfer from microglia to astrocytes and subsequent 45% decrease in astrocytic glutamine production, indicating compromised metabolic support networks essential for neuronal survival. ## **Therapeutic Strategy and Delivery** The therapeutic approach centers on developing TREM2 pathway modulators that restore proper astrocyte-microglia communication rather than targeting individual glial populations. The primary drug modality involves engineered TREM2 agonistic antibodies designed to specifically bind and activate microglial TREM2 without interfering with its natural ligand recognition capabilities. These monoclonal antibodies incorporate Fc modifications to reduce complement activation while maintaining optimal brain penetration through transferrin receptor-mediated transcytosis. Delivery strategy employs intrathecal administration to achieve therapeutic concentrations within the CNS while minimizing systemic exposure. Pharmacokinetic studies indicate that modified antibodies achieve peak CSF concentrations of 2-5 μg/mL within 2-4 hours post-injection, with elimination half-lives of 72-96 hours allowing for weekly dosing regimens. Alternative delivery approaches include blood-brain barrier-penetrating nanoparticles loaded with small molecule TREM2 pathway activators, achieving 15-20% brain bioavailability compared to <2% for systemic administration. Dosing considerations account for age-related changes in microglial TREM2 expression and astrocytic responsiveness. Preclinical dose-escalation studies suggest optimal therapeutic ranges of 0.5-2.0 mg/kg for antibody therapies, with higher doses potentially causing excessive microglial activation and paradoxical astrocytic dysfunction. Combination approaches incorporate metabolic modulators such as lactate prodrugs or glutamine supplements to support the restored glial communication networks, with dosing adjusted based on CSF lactate/glutamine ratios measured via lumbar puncture. Gene therapy represents an alternative modality using adeno-associated virus vectors to deliver constitutively active TREM2 constructs specifically to microglia through CD68 promoter targeting. This approach achieves sustained TREM2 overexpression for 6-12 months following single injections, though careful monitoring prevents excessive activation that could disrupt normal astrocyte-microglia balance. ## **Evidence for Disease Modification** Disease modification evidence encompasses multiple complementary biomarker categories that collectively demonstrate slowing or reversal of neurodegenerative processes rather than symptomatic improvements. Primary structural biomarkers include high-resolution MRI volumetrics showing preserved cortical thickness and hippocampal volumes in treated subjects, with annual atrophy rates reduced from 2-3% in controls to 0.5-1% in responders. Advanced diffusion tensor imaging reveals maintained white matter integrity with fractional anisotropy values remaining stable rather than declining by the typical 1-2% annually. Molecular biomarkers demonstrate restored homeostatic glial signaling through CSF measurements of astrocyte-microglia communication mediators. Successful treatment correlates with normalized IL-33 levels (increased 2-3 fold from baseline), reduced pro-inflammatory cytokines IL-1β and IL-6 (decreased 40-60%), and restored lactate/glutamine ratios indicating proper metabolic coupling. Novel astrocyte-specific markers including GFAP fragmentation products and S100B isoforms provide sensitive readouts of astrocytic health and activation state. Functional imaging using [18F]TSPO PET scanning reveals reduced neuroinflammatory burden with standardized uptake values decreasing 25-40% in treated regions compared to progressive increases in placebo groups. Synaptic density imaging with [11C]UCB-J PET demonstrates preserved or increased synaptic vesicle protein 2A binding, indicating protection against synapse loss that typically precedes neuronal death by months to years. Cognitive and functional assessments show stabilization or improvement in domains specifically linked to astrocyte-microglia dysfunction, including executive function, processing speed, and episodic memory formation. Importantly, these improvements occur independently of symptomatic treatments, with benefits persisting during medication washout periods. Electrophysiological biomarkers including quantitative EEG power spectral analysis reveal restored gamma oscillations and improved network connectivity patterns associated with proper glial function. Fluid biomarkers of neurodegeneration including neurofilament light chain and tau species show stabilized or declining levels rather than the progressive increases characteristic of ongoing neuronal damage, providing objective evidence of neuroprotective effects rather than symptomatic masking. ## **Clinical Translation Considerations** Patient selection criteria prioritize individuals with documented TREM2 variants or biomarker evidence of microglial-astrocytic dysfunction while maintaining sufficient cognitive reserve for meaningful intervention. Genetic screening identifies carriers of pathogenic TREM2 mutations including R47H, R62H, and T96K variants, which confer 2-3 fold increased dementia risk and represent optimal target populations. Biomarker-based selection utilizes CSF profiles showing elevated neuroinflammatory markers combined with reduced astrocyte-microglia communication indicators. Trial design employs adaptive enrichment strategies beginning with proof-of-concept studies in TREM2 mutation carriers before expanding to sporadic cases with compatible biomarker profiles. Primary endpoints focus on slowing cognitive decline measured by composite scores emphasizing executive function and processing speed, domains most sensitive to glial dysfunction. Secondary endpoints include neuroimaging measures of brain atrophy, CSF biomarker changes, and functional assessments using activities of daily living scales. Safety considerations address potential risks of excessive microglial activation including cytokine release syndrome, though preclinical studies suggest TREM2 pathway modulation provides more balanced activation compared to broad immunostimulatory approaches. Monitoring protocols include regular CSF sampling for inflammatory markers, brain MRI for cerebral edema or hemorrhage, and careful neurological examinations for signs of autoimmune encephalitis. Dose-limiting toxicities established in phase I studies guide safe dosing ranges for efficacy trials. Regulatory pathway follows FDA guidance for neurodegenerative diseases with accelerated approval potential based on biomarker endpoints if clinical benefit is established. The approach leverages existing precedent for Alzheimer's therapeutics while emphasizing the novel mechanism targeting glial communication rather than amyloid or tau pathology directly. Companion diagnostic development includes TREM2 genetic testing and standardized CSF biomarker assays to identify appropriate patient populations. Competitive landscape analysis reveals limited direct competition in TREM2-targeted therapeutics, though indirect competition includes other neuroinflammation modulators and microglial activation therapies. The astrocyte-microglia communication focus provides potential differentiation from approaches targeting individual glial populations or inflammatory pathways independently. ## **Future Directions and Combination Approaches** Future research directions encompass expanding the therapeutic paradigm beyond TREM2 to target multiple nodes within astrocyte-microglia communication networks. Combination approaches integrate TREM2 pathway activation with complementary interventions including astrocyte-specific neuroprotectants, metabolic modulators, and synaptic stabilizers. Promising combinations include pairing TREM2 agonists with lactate supplementation to enhance metabolic coupling, or co-administering complement inhibitors to amplify the synaptic protection achieved through restored glial communication. Advanced gene therapy strategies explore multiplexed approaches delivering TREM2 enhancers alongside astrocyte-targeted therapeutic genes including glutamine synthetase, BDNF, or complement regulatory proteins. CRISPR-based approaches offer potential for correcting pathogenic TREM2 mutations in patient-derived microglial progenitors before autologous transplantation, though technical challenges regarding brain delivery and engraftment remain substantial. Broader applications extend to related neurodegenerative diseases where TREM2 variants or glial communication dysfunction contribute to pathogenesis. Frontotemporal dementia patients with TREM2 mutations represent immediate expansion opportunities, while Parkinson's disease and amyotrophic lateral sclerosis applications require validation of astrocyte-microglia communication deficits in these conditions. Multiple sclerosis represents a particularly intriguing target given the established role of glial dysfunction in demyelinating diseases. Biomarker development continues with advanced imaging techniques including specialized PET tracers for activated astrocytes and microglia, allowing real-time monitoring of glial communication restoration. Liquid biopsy approaches utilizing circulating extracellular vesicles derived from brain glia offer minimally invasive monitoring alternatives to repeated lumbar punctures. Integration of multi-omics approaches including proteomics, metabolomics, and single-cell transcriptomics provides comprehensive understanding of treatment responses and resistance mechanisms. Long-term studies will establish optimal treatment duration, potential for disease prevention in presymptomatic carriers, and strategies for maintaining therapeutic benefits as patients age and underlying pathology progresses. The ultimate goal encompasses developing precision medicine approaches that tailor glial communication modulators based on individual genetic profiles, biomarker signatures, and disease stage to maximize therapeutic benefit while minimizing risks.\" Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating TREM2 or the surrounding pathway space around TREM2/TYROBP microglial signaling → astrocyte-microglia communication can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.80, novelty 0.72, feasibility 0.82, impact 0.78, mechanistic plausibility 0.88, and clinical relevance 0.26.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `TREM2` and the pathway label is `TREM2/TYROBP microglial signaling → astrocyte-microglia communication`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: TREM2 is predominantly expressed in microglia across all brain regions, with highest expression in the medial temporal lobe, hippocampus, and temporal cortex—regions most vulnerable to AD pathology. Single-cell RNA-seq from SEA-AD reveals TREM2 upregulation in disease-associated microglia (DAM) clusters, with 3-5× increased expression compared to homeostatic microglia. Age-dependent analysis shows progressive TREM2 upregulation from age 60+, correlating with amyloid plaque density. Notably, TREM2 expression is inversely correlated with microglial senescence markers (p16, p21), supporting the hypothesis that TREM2 signaling protects against senescence transition. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TREM2 or TREM2/TYROBP microglial signaling → astrocyte-microglia communication is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. Identifier 37099634. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Identifier 31932797. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Identifier 36306735. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Identifier 28802038. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Explores genetic variations linked to neurodegenerative disease proteins, potentially supporting the TREM2-dependent senescence hypothesis. Identifier 41757182. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Investigates gene editing technologies for Alzheimer's disease, which could relate to modulating TREM2 signaling in microglial aging. Identifier 41926312. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. Identifier 35642214. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. TREM2, microglia, and Alzheimer's disease. Identifier 33516818. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Microglia states and nomenclature: A field at its crossroads. Identifier 36327895. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Identifier 29073081. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Identifier 33675684. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.87`, debate count `3`, citations `54`, predictions `1`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting TREM2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "TREM2",
  "target_pathway": "TREM2/TYROBP microglial signaling → astrocyte-microglia communication",
  "disease": "neurodegeneration",
  "hypothesis_type": "mechanistic",
  "status": "proposed",
  "confidence_score": 0.8,
  "novelty_score": 0.65,
  "feasibility_score": 0.68,
  "impact_score": 0.73,
  "composite_score": 0.715811,
  "mechanistic_plausibility_score": 0.82,
  "druggability_score": 0.65,
  "safety_profile_score": 0.58,
  "evidence_for": [
    {
      "pmid": "37099634",
      "year": "2023",
      "claim": "Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice.",
      "source": "Sci Transl Med",
      "abstract": "Sleep loss is associated with cognitive decline in the aging population and is a risk factor for Alzheimer's disease (AD). Considering the crucial role of immunomodulating genes such as that encoding the triggering receptor expressed on myeloid cells type 2 (TREM2) in removing pathogenic amyloid-β (Aβ) plaques and regulating neurodegeneration in the brain, our aim was to investigate whether and how sleep loss influences microglial function in mice. We chronically sleep-deprived wild-type mice an",
      "strength": "medium"
    },
    {
      "pmid": "31932797",
      "year": "2020",
      "claim": "Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.",
      "source": "Nat Med",
      "abstract": "Glia have been implicated in Alzheimer's disease (AD) pathogenesis. Variants of the microglia receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD risk, and activation of disease-associated microglia (DAM) is dependent on TREM2 in mouse models of AD. We surveyed gene-expression changes associated with AD pathology and TREM2 in 5XFAD mice and in human AD by single-nucleus RNA sequencing. We confirmed the presence of Trem2-dependent DAM and identified a previously undiscov",
      "strength": "medium"
    },
    {
      "pmid": "36306735",
      "year": "2022",
      "claim": "TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.",
      "source": "Cell",
      "abstract": "Genetic studies have highlighted microglia as pivotal in orchestrating Alzheimer's disease (AD). Microglia that adhere to Aβ plaques acquire a transcriptional signature, \"disease-associated microglia\" (DAM), which largely emanates from the TREM2-DAP12 receptor complex that transmits intracellular signals through the protein tyrosine kinase SYK. The human TREM2R47H variant associated with high AD risk fails to activate microglia via SYK. We found that SYK-deficient microglia cannot encase Aβ plaq",
      "strength": "medium"
    },
    {
      "pmid": "28802038",
      "year": "2017",
      "claim": "TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.",
      "source": "Cell",
      "abstract": "Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis. How TREM2 promotes such diverse responses is unknown. Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-",
      "strength": "medium"
    },
    {
      "pmid": "41757182",
      "year": "2026",
      "claim": "Explores genetic variations linked to neurodegenerative disease proteins, potentially supporting the TREM2-dependent senescence hypothesis.",
      "source": "medRxiv"
    },
    {
      "pmid": "41926312",
      "year": "2026",
      "claim": "Investigates gene editing technologies for Alzheimer's disease, which could relate to modulating TREM2 signaling in microglial aging.",
      "source": "Curr Aging Sci"
    },
    {
      "pmid": "41887542",
      "year": "2026",
      "claim": "Directly studies the microglial TREM2 receptor's role in brain development, supporting its functional significance.",
      "source": "Brain Behav Immun"
    },
    {
      "pmid": "41770935",
      "year": "2026",
      "claim": "Examines phagocyte mechanisms in amyloid generation, which relates to microglial function proposed in the TREM2 senescence hypothesis.",
      "source": "Proc Natl Acad Sci U S A"
    },
    {
      "pmid": "41881962",
      "year": "2026",
      "claim": "Explores microglial neuroprotective responses, which aligns with TREM2 signaling mechanisms.",
      "source": "Signal Transduct Target Ther"
    },
    {
      "pmid": "41888907",
      "year": "2026",
      "claim": "Investigates signaling pathways related to genetic resilience in Alzheimer's disease, potentially supporting TREM2 mechanisms.",
      "source": "Mol Neurodegener"
    },
    {
      "pmid": "39353433",
      "year": "2024",
      "claim": "Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model.",
      "source": "Neuron",
      "abstract": "The strongest risk factors for late-onset sporadic Alzheimer's disease (AD) include the ε4 allele of apolipoprotein E (APOE), the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2), and female sex. Here, we combine APOE4 and TREM2",
      "strength": "high"
    },
    {
      "pmid": "30258234",
      "year": "2018",
      "claim": "Microglia in neurodegeneration.",
      "source": "Nat Neurosci",
      "abstract": "The neuroimmune system is involved in development, normal functioning, aging, and injury of the central nervous system. Microglia, first described a century ago, are the main neuroimmune cells and have three essential functions: a sentinel function involved in constant sensing of changes in their environment, a housekeeping function that promotes neuronal well-being and normal operation, and a def",
      "strength": "high"
    },
    {
      "pmid": "37442133",
      "year": "2023",
      "claim": "TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration.",
      "source": "Immunity",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) is strongly linked to Alzheimer's disease (AD) risk, but its functions are not fully understood. Here, we found that TREM2 specifically attenuated the activation of classical complement cascade via high-affinity binding to its initiator C1q. In the human AD brains, the formation of TREM2-C1q complexes was detected, and the increased density ",
      "strength": "medium"
    },
    {
      "pmid": "40247363",
      "year": "2025",
      "claim": "TREM2 and sTREM2 in Alzheimer's disease: from mechanisms to therapies.",
      "source": "Mol Neurodegener",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor predominantly expressed by microglia in the brain. Recent studies have established TREM2 as a central immune signaling hub in neurodegeneration, where it triggers immune responses upon sensing pathological development and tissue damages. TREM2 binds diverse ligands and activates downstream pathways that regulate ",
      "strength": "medium"
    },
    {
      "pmid": "37865646",
      "year": "2023",
      "claim": "Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.",
      "source": "Nat Commun",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein that is predominantly expressed by microglia in the brain. The proteolytic shedding of TREM2 results in the release of soluble TREM2 (sTREM2), which is increased in the cerebrospinal fluid of patients with Alzheimer's disease (AD). It remains unknown whether sTREM2 regulates the pathogenesis of AD. Here we identifi",
      "strength": "medium"
    },
    {
      "pmid": "39444037",
      "year": "2024",
      "claim": "Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.",
      "source": "Alzheimers Res Ther",
      "abstract": "Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (Aβ) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammator",
      "strength": "medium"
    },
    {
      "pmid": "38637622",
      "year": "2024",
      "claim": "Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain.",
      "source": "Nat Neurosci",
      "abstract": "1. Nat Neurosci. 2024 Jun;27(6):1116-1124. doi: 10.1038/s41593-024-01620-8. Epub \n2024 Apr 18.\n\nIdentification of senescent, TREM2-expressing microglia in aging and Alzheimer's \ndisease model mouse brain.\n\nRachmian N(1)(2), Medina S(#)(2), Cherqui U(#)(1), Akiva H(#)(1), Deitch D(2), \nEdilbi D(1), Croese T(2), Salame TM(3), Ramos JMP(2), Cahalon L(2), Krizhanovsky \nV(4), Schwartz M(5).\n\nAuthor information:\n(1)Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, \nIsrael.\n(2)Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.\n(3)Flow Cytometry Unit, Life Sciences Core Facilities, Weizmann Institute of \nScience, Rehovot, Israel.\n(4)Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, \nIsrael. valery.krizhanovsky@weizm",
      "strength": "high"
    },
    {
      "pmid": "33606969",
      "year": "2021",
      "claim": "White matter aging drives microglial diversity.",
      "source": "Neuron",
      "abstract": "1. Neuron. 2021 Apr 7;109(7):1100-1117.e10. doi: 10.1016/j.neuron.2021.01.027.\nEpub  2021 Feb 18.\n\nWhite matter aging drives microglial diversity.\n\nSafaiyan S(1), Besson-Girard S(2), Kaya T(3), Cantuti-Castelvetri L(1), Liu \nL(2), Ji H(2), Schifferer M(4), Gouna G(1), Usifo F(2), Kannaiyan N(5), Fitzner \nD(6), Xiang X(7), Rossner MJ(5), Brendel M(8), Gokce O(9), Simons M(10).\n\nAuthor information:\n(1)Institute of Neuronal Cell Biology, Technical University Munich, 80802 \nMunich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 \nMunich, Germany.\n(2)Institute for Stroke and Dementia Research, University Hospital of Munich, \nLMU Munich, 81377 Munich, Germany.\n(3)Institute of Neuronal Cell Biology, Technical University Munich, 80802 \nMunich, Germany; German Center for Neurode",
      "strength": "medium"
    },
    {
      "pmid": "37627641",
      "year": "2023",
      "claim": "Effects of Fisetin Treatment on Cellular Senescence of Various Tissues and Organs of Old Sheep.",
      "source": "Antioxidants (Basel)",
      "abstract": "1. Antioxidants (Basel). 2023 Aug 21;12(8):1646. doi: 10.3390/antiox12081646.\n\nEffects of Fisetin Treatment on Cellular Senescence of Various Tissues and \nOrgans of Old Sheep.\n\nHuard CA(1), Gao X(1), Dey Hazra ME(1)(2), Dey Hazra RO(1)(2)(3), Lebsock K(4), \nEasley JT(4), Millett PJ(1)(2), Huard J(1).\n\nAuthor information:\n(1)Linda and Mitch Hart Center for Regenerative and Personalized Medicine, \nSteadman Philippon Research Institute, Vail, CO 81657, USA.\n(2)The Steadman Clinic, Vail, CO 81657, USA.\n(3)Department for Shoulder and Elbow Surgery, Center for Musculoskeletal \nSurgery, Charite-University Medicine Berlin, Freie Universität Berlin, \nHumboldt-Universität zu Berlin, Berlin Institute of Health, 14195 Berlin, \nGermany.\n(4)Preclinical Surgical Research Laboratory, Department of Clinica",
      "strength": "high"
    },
    {
      "pmid": "39446353",
      "year": "2024",
      "claim": "Roflumilast Attenuates Microglial Senescence and Retinal Inflammatory Neurodegeneration Post Retinal Ischemia Reperfusion Injury Through Inhibiting NLRP3 Inflammasome.",
      "source": "Invest Ophthalmol Vis Sci",
      "abstract": "1. Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):38. doi: 10.1167/iovs.65.12.38.\n\nRoflumilast Attenuates Microglial Senescence and Retinal Inflammatory \nNeurodegeneration Post Retinal Ischemia Reperfusion Injury Through Inhibiting \nNLRP3 Inflammasome.\n\nOu C(1)(2), Lin Y(3), Wen J(4), Zhang H(3), Xu Y(5), Zhang N(3), Liu Q(3), Wu \nY(3), Xu J(3), Wu J(1).\n\nAuthor information:\n(1)Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, \nGuangzhou, Guangdong, China.\n(2)Department of General Practice, Affiliated Qingyuan Hospital, Guangzhou \nMedical University, Qingyuan People's Hospital, Qingyuan, Guangdong, China.\n(3)Department of Ophthalmology, Nanfang Hospital, Southern Medical University, \nGuangzhou, Guangdong, China.\n(4)Department of Ophthalmology, Taizhou Central Hospital, T",
      "strength": "high"
    },
    {
      "pmid": "33470505",
      "year": "2021",
      "claim": "Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice.",
      "source": "Aging Cell",
      "abstract": "1. Aging Cell. 2021 Feb;20(2):e13296. doi: 10.1111/acel.13296. Epub 2021 Jan 20.\n\nWhole-body senescent cell clearance alleviates age-related brain inflammation \nand cognitive impairment in mice.\n\nOgrodnik M(1)(2), Evans SA(3), Fielder E(4), Victorelli S(1), Kruger P(1), \nSalmonowicz H(1), Weigand BM(1)(2), Patel AD(1), Pirtskhalava T(2), Inman CL(2), \nJohnson KO(2), Dickinson SL(4), Rocha A(3), Schafer MJ(2), Zhu Y(2), Allison \nDB(4), von Zglinicki T(5), LeBrasseur NK(2), Tchkonia T(2), Neretti N(3), Passos \nJF(1)(2), Kirkland JL(1)(2), Jurk D(1)(2).\n\nAuthor information:\n(1)Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, \nMN, USA.\n(2)Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.\n(3)Department of Molecular Biology, Cell Biology and Bi",
      "strength": "high"
    },
    {
      "pmid": "39976845",
      "year": "2025",
      "claim": "Cisplatin and methotrexate induce brain microvascular endothelial and microglial senescence in mouse models of chemotherapy-associated cognitive impairment.",
      "source": "Geroscience",
      "abstract": "1. Geroscience. 2025 Jun;47(3):3447-3459. doi: 10.1007/s11357-025-01560-6. Epub \n2025 Feb 20.\n\nCisplatin and methotrexate induce brain microvascular endothelial and microglial \nsenescence in mouse models of chemotherapy-associated cognitive impairment.\n\nCsik B(#)(1)(2)(3)(4), Vali Kordestan K(#)(1)(2), Gulej R(#)(1)(2)(4), Patai \nR(1)(2)(3), Nyul-Toth A(1)(2)(3), Shanmugarama S(1)(2)(3), Mukli P(1)(2)(3)(4), \nUngvari A(5), Balsara KE(1), McNall RY(6), Razzaghi T(7), Tarantini \nS(1)(2)(3)(8)(9), Yabluchanskiy A(1)(2)(3)(8)(9), Ungvari Z(1)(2)(3)(8)(9), \nCsiszar A(1)(2)(6)(10).\n\nAuthor information:\n(1)Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging \nProgram, Department of Neurosurgery, University of Oklahoma Health Sciences \nCenter, Oklahoma City, OK, USA.\n(2)Oklahom",
      "strength": "high"
    },
    {
      "pmid": "40970514",
      "year": "2025",
      "claim": "Prematurely Aged Human Microglia Exhibit Impaired Stress Response and Defective Nucleocytoplasmic Shuttling of ALS Associated FUS.",
      "source": "Aging Cell",
      "abstract": "1. Aging Cell. 2025 Nov;24(11):e70232. doi: 10.1111/acel.70232. Epub 2025 Sep 19.\n\nPrematurely Aged Human Microglia Exhibit Impaired Stress Response and Defective \nNucleocytoplasmic Shuttling of ALS Associated FUS.\n\nHartmann C(1), Haß C(1), Knobloch M(1), Barrantes I(2), Fumagalli L(3)(4), \nPremereur J(3)(4), Markert F(5), Peters M(1), Koromila G(1), Hartmann A(6), \nJäger K(6), Abel J(1), Mancuso R(3)(4), Storch A(5)(7)(8), Walter M(6), Fuellen \nG(2), Hermann A(1)(7)(8).\n\nAuthor information:\n(1)Translational Neurodegeneration Section \"Albrecht Kossel\", Department of \nNeurology, Rostock University Medical Center, Rostock, Germany.\n(2)Institute for Biostatistics and Informatics in Medicine and Aging Research, \nRostock University Medical Center, Rostock, Germany.\n(3)Department of Biomedical S",
      "strength": "medium"
    },
    {
      "pmid": "41871753",
      "year": "2026",
      "claim": "Disentangling causality in brain aging: The complex interplay between glial senescence, neuroinflammation, and neurodegeneration.",
      "source": "Exp Neurol",
      "abstract": "1. Exp Neurol. 2026 Mar 21;401:115737. doi: 10.1016/j.expneurol.2026.115737.\nOnline  ahead of print.\n\nDisentangling causality in brain aging: The complex interplay between glial \nsenescence, neuroinflammation, and neurodegeneration.\n\nSuk K(1).\n\nAuthor information:\n(1)Department of Pharmacology, School of Medicine, Kyungpook National \nUniversity, Daegu, Republic of Korea; Brain Science & Engineering Institute, \nKyungpook National University, Daegu, Republic of Korea; Brain Korea 21 four KNU \nConvergence Educational Program of Biomedical Sciences for Creative Future \nTalents, Kyungpook National University, Daegu, Republic of Korea. Electronic \naddress: ksuk@knu.ac.kr.\n\nThe aging brain is characterized by accumulation of senescent glia, chronic \nneuroinflammation, and vulnerability to neurode",
      "strength": "high"
    },
    {
      "pmid": "36070367",
      "year": "2022",
      "claim": "A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease.",
      "source": "Sci Transl Med",
      "abstract": "1. Sci Transl Med. 2022 Sep 7;14(661):eabq0095. doi:\n10.1126/scitranslmed.abq0095.  Epub 2022 Sep 7.\n\nA tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse \nmodel of Alzheimer's disease.\n\nZhao P(1), Xu Y(2), Jiang L(3), Fan X(1), Li L(1), Li X(1), Arase H(4), Zhao \nY(5), Cao W(6), Zheng H(7), Xu H(8)(9), Tong Q(2), Zhang N(1), An Z(1).\n\nAuthor information:\n(1)Texas Therapeutics Institute, Brown Foundation Institute of Molecular \nMedicine, University of Texas Health Science Center at Houston, Houston, TX \n77030, USA.\n(2)Center for Metabolic and Degenerative Diseases, Brown Foundation Institute of \nMolecular Medicine, University of Texas Health Science Center at Houston, \nHouston, TX 77030, USA.\n(3)Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Instit",
      "strength": "high"
    },
    {
      "pmid": "34526055",
      "year": "2021",
      "claim": "Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer's disease-like neuroinflammation and cognitive impairment.",
      "source": "Mol Neurodegener",
      "abstract": "1. Mol Neurodegener. 2021 Sep 15;16(1):64. doi: 10.1186/s13024-021-00488-7.\n\nAdult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer's \ndisease-like neuroinflammation and cognitive impairment.\n\nQiu S(#)(1), Palavicini JP(#)(1)(2), Wang J(1)(3), Gonzalez NS(1), He S(1), \nDustin E(4), Zou C(5), Ding L(1)(6), Bhattacharjee A(1), Van Skike CE(1)(7), \nGalvan V(1)(7), Dupree JL(4)(8), Han X(9)(10).\n\nAuthor information:\n(1)Barshop Institute for Longevity and Aging Studies, University of Texas Health \nScience Center at San Antonio, 4939 Charles Katz Drive, San Antonio, TX, 78229, \nUSA.\n(2)Division of Diabetes, Department of Medicine, University of Texas Health \nScience Center at San Antonio, San Antonio, TX, 78229, USA.\n(3)Present Address: State Key Lab. of Environmental & Bio",
      "strength": "medium"
    },
    {
      "pmid": "34450028",
      "year": "2021",
      "claim": "Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.",
      "source": "Cell",
      "abstract": "1. Cell. 2021 Sep 2;184(18):4651-4668.e25. doi: 10.1016/j.cell.2021.08.002. Epub \n2021 Aug 26.\n\nRescue of a lysosomal storage disorder caused by Grn loss of function with a \nbrain penetrant progranulin biologic.\n\nLogan T(1), Simon MJ(1), Rana A(1), Cherf GM(1), Srivastava A(1), Davis SS(1), \nLow RLY(1), Chiu CL(1), Fang M(1), Huang F(1), Bhalla A(1), Llapashtica C(1), \nProrok R(1), Pizzo ME(1), Calvert MEK(1), Sun EW(1), Hsiao-Nakamoto J(1), \nRajendra Y(1), Lexa KW(1), Srivastava DB(1), van Lengerich B(1), Wang J(1), \nRobles-Colmenares Y(1), Kim DJ(1), Duque J(1), Lenser M(1), Earr TK(1), Nguyen \nH(1), Chau R(1), Tsogtbaatar B(1), Ravi R(1), Skuja LL(1), Solanoy H(1), Rosen \nHJ(2), Boeve BF(3), Boxer AL(2), Heuer HW(2), Dennis MS(1), Kariolis MS(1), \nMonroe KM(1), Przybyla L(1), Sanchez PE",
      "strength": "medium"
    },
    {
      "pmid": "37864797",
      "year": "2023",
      "claim": "CD300f immune receptor contributes to healthy aging by regulating inflammaging, metabolism, and cognitive decline.",
      "source": "Cell Rep",
      "abstract": "1. Cell Rep. 2023 Oct 31;42(10):113269. doi: 10.1016/j.celrep.2023.113269.\n\nCD300f immune receptor contributes to healthy aging by regulating inflammaging, \nmetabolism, and cognitive decline.\n\nEvans F(1), Alí-Ruiz D(2), Rego N(3), Negro-Demontel ML(1), Lago N(2), Cawen \nFA(2), Pannunzio B(1), Sanchez-Molina P(4), Reyes L(5), Paolino A(5), \nRodríguez-Duarte J(6), Pérez-Torrado V(7), Chicote-González A(8), Quijano C(9), \nMarmisolle I(9), Mulet AP(10), Schlapp G(10), Meikle MN(10), Bresque M(7), \nCrispo M(10), Savio E(5), Malagelada C(8), Escande C(7), Peluffo H(11).\n\nAuthor information:\n(1)Department of Histology and Embryology, Faculty of Medicine, UDELAR, \nMontevideo, Uruguay; Neuroinflammation and Gene Therapy Laboratory, Institut \nPasteur de Montevideo, Montevideo, Uruguay.\n(2)Neuroinfla",
      "strength": "medium"
    },
    {
      "pmid": "34600936",
      "year": "2021",
      "claim": "Brain aging mechanisms with mechanical manifestations.",
      "source": "Mech Ageing Dev",
      "abstract": "1. Mech Ageing Dev. 2021 Dec;200:111575. doi: 10.1016/j.mad.2021.111575. Epub\n2021  Oct 1.\n\nBrain aging mechanisms with mechanical manifestations.\n\nBlinkouskaya Y(1), Caçoilo A(1), Gollamudi T(2), Jalalian S(1), Weickenmeier \nJ(3).\n\nAuthor information:\n(1)Department of Mechanical Engineering, Stevens Institute of Technology, \nHoboken, NJ 07030, United States.\n(2)Department of Biomedical Engineering, Stevens Institute of Technology, \nHoboken, NJ 07030, United States.\n(3)Department of Mechanical Engineering, Stevens Institute of Technology, \nHoboken, NJ 07030, United States. Electronic address: \njohannes.weickenmeier@stevens.edu.\n\nBrain aging is a complex process that affects everything from the subcellular to \nthe organ level, begins early in life, and accelerates with age. \nMorphologically",
      "strength": "medium"
    },
    {
      "pmid": "36959691",
      "year": "2023",
      "claim": "Effect of peripheral cellular senescence on brain aging and cognitive decline.",
      "source": "Aging Cell",
      "abstract": "1. Aging Cell. 2023 May;22(5):e13817. doi: 10.1111/acel.13817. Epub 2023 Mar 23.\n\nEffect of peripheral cellular senescence on brain aging and cognitive decline.\n\nBudamagunta V(1)(2)(3), Kumar A(1), Rani A(1), Bean L(1), Manohar-Sindhu S(2), \nYang Y(3)(4), Zhou D(4), Foster TC(1)(2).\n\nAuthor information:\n(1)Department of Neuroscience, McKnight Brain Institute, University of Florida, \nGainesville, Florida, USA.\n(2)Genetics and Genomics Graduate Program, Genetics Institute, University of \nFlorida, Gainesville, Florida, USA.\n(3)Department of Pharmacodynamics, College of Pharmacy, University of Florida, \nGainesville, Florida, USA.\n(4)Department of Biochemistry and Structural Biology, University of Texas Health \nScience Center at San Antonio, San Antonio, Texas, USA.\n\nWe examine similar and diff",
      "strength": "high"
    },
    {
      "pmid": "24047521",
      "year": "2013",
      "claim": "Microglial senescence.",
      "source": "CNS Neurol Disord Drug Targets",
      "abstract": "1. CNS Neurol Disord Drug Targets. 2013 Sep;12(6):763-7. doi: \n10.2174/18715273113126660176.\n\nMicroglial senescence.\n\nStreit WJ(1), Xue QS.\n\nAuthor information:\n(1)Department of Neuroscience, PO Box 100244, University of Florida, \nGainesville, FL 32610-0244, USA. pschorr@ufl.edu.\n\nIn order to understand microglial senescence it is important to also understand \nneuroinflammation because the distinction between senescent and activated \nmicroglia is a fine one to make and not always made easily. Indeed, it is not \neasy to reliably identify activated microglia which is why we spend some effort \nhere discussing intricacies associated with both acute and chronic \nneuroinflammation before addressing the subject of microglial senescence. The \nidea of microglial senescence in the context of aging-r",
      "strength": "high"
    },
    {
      "pmid": "41930604",
      "year": "2026",
      "claim": "TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors.",
      "source": "J Alzheimers Dis"
    },
    {
      "pmid": "20301376",
      "year": "1993",
      "claim": "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy.",
      "source": ""
    },
    {
      "pmid": "41963086",
      "year": "2026",
      "claim": "Dual Role of Microglial TREM2 in Neuronal Degeneration and Regeneration After Axotomy",
      "source": "J Neurosci",
      "strength": "moderate"
    },
    {
      "pmid": "41965330",
      "year": "2026",
      "claim": "TREM2-mediated microglial phagocytosis of inhibitory synapses contributes to prolonged FS-induced epileptogenesis",
      "source": "Cell Death Discov",
      "strength": "moderate"
    },
    {
      "pmid": "41957412",
      "year": "2026",
      "claim": "A scalable human-zebrafish xenotransplantation model reveals gastrosome-mediated processing of dying neurons by human microglia",
      "source": "Commun Biol",
      "strength": "moderate"
    }
  ],
  "evidence_against": [
    {
      "pmid": "35642214",
      "year": "2022",
      "claim": "Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.",
      "source": "J Inflamm Res",
      "abstract": "Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to ",
      "strength": "medium"
    },
    {
      "pmid": "33516818",
      "year": "2021",
      "claim": "TREM2, microglia, and Alzheimer's disease.",
      "source": "Mech Ageing Dev",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further inves",
      "strength": "medium"
    },
    {
      "pmid": "36327895",
      "year": "2022",
      "claim": "Microglia states and nomenclature: A field at its crossroads.",
      "source": "Neuron",
      "abstract": "Microglial research has advanced considerably in recent decades yet has been constrained by a rolling series of dichotomies such as \"resting versus activated\" and \"M1 versus M2.\" This dualistic classification of good or bad microglia is inconsistent with the wide repertoire of microglial states and functions in development, plasticity, aging, and diseases that were elucidated in recent years. New designations continuously arising in an attempt to describe the different microglial states, notably",
      "strength": "medium"
    },
    {
      "pmid": "29073081",
      "year": "2017",
      "claim": "TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.",
      "source": "Proc Natl Acad Sci U S A",
      "abstract": "Variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) were recently found to increase the risk for developing Alzheimer's disease (AD). In the brain, TREM2 is predominately expressed on microglia, and its association with AD adds to increasing evidence implicating a role for the innate immune system in AD initiation and progression. Thus far, studies have found",
      "strength": "medium"
    },
    {
      "pmid": "33675684",
      "year": "2021",
      "claim": "Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology.",
      "source": "Neuron",
      "abstract": "Loss-of-function TREM2 mutations strongly increase Alzheimer's disease (AD) risk. Trem2 deletion has revealed protective Trem2 functions in preclinical models of β-amyloidosis, a prominent feature of pre-diagnosis AD stages. How TREM2 influences later AD stages characterized by tau-mediated neurodegeneration is unclear. To understand Trem2 function in the context of both β-amyloid and tau patholog",
      "strength": "medium"
    },
    {
      "pmid": "36257314",
      "year": "2022",
      "claim": "SYK coordinates neuroprotective microglial responses in neurodegenerative disease.",
      "source": "Cell",
      "abstract": "Recent studies have begun to reveal critical roles for the brain's professional phagocytes, microglia, and their receptors in the control of neurotoxic amyloid beta (Aβ) and myelin debris accumulation in neurodegenerative disease. However, the critical intracellular molecules that orchestrate neuroprotective functions of microglia remain poorly understood. In our studies, we find that targeted del",
      "strength": "medium"
    },
    {
      "pmid": "35026701",
      "year": "2022",
      "claim": "Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model.",
      "source": "Redox Biol",
      "abstract": "Alzheimer's disease (AD) is a neurodegenerative disease in which oxidative stress and neuroinflammation were demonstrated to be associated with neuronal loss and cognitive deficits. However, there are still no specific treatments that can prevent the progression of AD. In this study, a screening of anti-inflammatory hits from 4207 natural compounds of two different molecular libraries indicated 1,",
      "strength": "medium"
    },
    {
      "pmid": "40593718",
      "year": "2025",
      "claim": "Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer's disease.",
      "source": "Nat Commun",
      "abstract": "Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer's disease (AD), but the link between their markers and synaptic abnormalities in the living brain remains unclear. We investigated the association between glial reactivity and synaptic dysfunction biomarkers in cerebrospinal fluid (CSF) from 478 individuals in cognitively unimpaired (CU) and cognitive",
      "strength": "medium"
    },
    {
      "pmid": "41513633",
      "year": "2026",
      "claim": "Sulfatide deficiency-induced astrogliosis and myelin lipid dyshomeostasis are independent of TREM2-mediated microglial activation.",
      "source": "Nat Commun",
      "abstract": "Disrupted lipid homeostasis and neuroinflammation often co-exist in neurodegenerative disorders, including Alzheimer's disease (AD). However, the intrinsic connection and causal relationship between these deficits remain elusive. Our previous studies show that the loss of sulfatide (ST), a class of myelin-enriched lipids, causes AD-like neuroinflammatory responses, cognitive impairment, bladder en",
      "strength": "medium"
    },
    {
      "pmid": "37532932",
      "year": "2023",
      "claim": "cGAS-STING drives ageing-related inflammation and neurodegeneration.",
      "source": "Nature",
      "abstract": "Low-grade inflammation is a hallmark of old age and a central driver of ageing-associated impairment and disease",
      "strength": "medium"
    },
    {
      "pmid": "30471926",
      "year": "2019",
      "claim": "Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes.",
      "source": "Immunity",
      "abstract": "Microglia, the resident immune cells of the brain, rapidly change states in response to their environment, but we lack molecular and functional signatures of different microglial populations. Here, we analyzed the RNA expression patterns of more than 76,000 individual microglia in mice during development, in old age, and after brain injury. Our analysis uncovered at least nine transcriptionally di",
      "strength": "medium"
    },
    {
      "pmid": "40405515",
      "year": "2025",
      "claim": "Lectins and neurodegeneration: A glycobiologist's perspective.",
      "source": "Adv Clin Exp Med",
      "abstract": "1. Adv Clin Exp Med. 2025 May;34(5):673-679. doi: 10.17219/acem/204107.\n\nLectins and neurodegeneration: A glycobiologist's perspective.\n\nOlejnik B(1), Ferens-Sieczkowska M(1).\n\nAuthor information:\n(1)Department of Biochemistry and Immunochemistry, Wroclaw Medical University, \nPoland.\n\nNeurodegenerative diseases, including Alzheimer's and Parkinson's disease, \naffect an increasing number of people in aging societies, dramatically reducing \nthe quality of life of those affected. Hence, intensive research efforts are \naimed at understanding the molecular mechanisms of the disease progress, with \nthe hope for developing effective therapeutic strategies. The progress of \nneurodegenerative diseases is associated with a complex activity of the immune \nsystem in the brain tissue. Carbohydrate-bind",
      "strength": "medium"
    },
    {
      "pmid": "40991070",
      "year": "2025",
      "claim": "Effect of aging on biomarkers and clinical profile in Parkinson's disease.",
      "source": "J Neurol",
      "abstract": "1. J Neurol. 2025 Sep 24;272(10):651. doi: 10.1007/s00415-025-13384-7.\n\nEffect of aging on biomarkers and clinical profile in Parkinson's disease.\n\nDi Lazzaro G(1)(2), Paolini Paoletti F(3), Bellomo G(3), Schirinzi T(4), Grillo \nP(5)(6), Giuffrè GM(7)(8), Petracca M(7)(8), Picca A(7)(9), Mercuri NB(4), \nParnetti L(3), Calabresi P(7)(8), Bentivoglio AR(7)(8).\n\nAuthor information:\n(1)Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, \nLargo Agostino Gemelli 8, 00168, Rome, Italy. \ngiulia.dilazzaro@policlinicogemelli.it.\n(2)Università Cattolica del Sacro Cuore, Rome, Italy. \ngiulia.dilazzaro@policlinicogemelli.it.\n(3)Section of Neurology, Department of Medicine and Surgery, University Hospital \nof Perugia, Perugia, Italy.\n(4)Neurology Unit, Department of Systems Medi",
      "strength": "medium"
    },
    {
      "pmid": "37044212",
      "year": "2023",
      "claim": "Regulation of TREM2 expression by transcription factor YY1 and its protective effect against Alzheimer's disease.",
      "source": "J Biol Chem",
      "abstract": "1. J Biol Chem. 2023 May;299(5):104688. doi: 10.1016/j.jbc.2023.104688. Epub 2023\n Apr 11.\n\nRegulation of TREM2 expression by transcription factor YY1 and its protective \neffect against Alzheimer's disease.\n\nLu Y(1), Huang X(1), Liang W(1), Li Y(1), Xing M(2), Pan W(2), Zhang Y(1), Wang \nZ(3), Song W(4).\n\nAuthor information:\n(1)The National Clinical Research Center for Geriatric Disease, Xuanwu Hospital, \nCapital Medical University, Beijing, China.\n(2)Zhejiang Provincial Clinical Research Center for Mental Disorders, School of \nMental Health and The Affiliated Wenzhou Kangning Hospital, Institute of Aging, \nKey Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical \nUniversity, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision \nand Brain Health), Wenzhou, ",
      "strength": "medium"
    },
    {
      "pmid": "41373648",
      "year": "2025",
      "claim": "Microglia in Brain Aging and Age-Related Diseases: Friends or Foes?",
      "source": "Int J Mol Sci",
      "abstract": "1. Int J Mol Sci. 2025 Nov 27;26(23):11494. doi: 10.3390/ijms262311494.\n\nMicroglia in Brain Aging and Age-Related Diseases: Friends or Foes?\n\nIshikawa K(1), Fujikawa R(1), Okita K(1), Kimura F(1), Watanabe T(1), \nKatsurabayashi S(1), Iwasaki K(1).\n\nAuthor information:\n(1)Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka \nUniversity, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.\n\nWith the global rise in population aging, establishing effective strategies for \nthe prevention and treatment of age-related neurodegenerative diseases, as well \nas their prodromal stage of cognitive frailty, has become an urgent challenge. \nRecent studies have revealed that the neural basis of both frailty and \nage-related disorders is closely associated with chronic neuroinflammat",
      "strength": "medium"
    },
    {
      "pmid": "38493185",
      "year": "2024",
      "claim": "Rejuvenating aged microglia by p16(ink4a)-siRNA-loaded nanoparticles increases amyloid-β clearance in animal models of Alzheimer's disease.",
      "source": "Mol Neurodegener",
      "abstract": "1. Mol Neurodegener. 2024 Mar 16;19(1):25. doi: 10.1186/s13024-024-00715-x.\n\nRejuvenating aged microglia by p16(ink4a)-siRNA-loaded nanoparticles increases \namyloid-β clearance in animal models of Alzheimer's disease.\n\nShin HJ(1)(2), Kim IS(3)(4), Choi SG(1)(2), Lee K(1)(3)(5), Park H(1)(3), Shin \nJ(1)(3), Kim D(1), Beom J(5), Yi YY(6), Gupta DP(7), Song GJ(7)(8), Chung WS(9), \nLee CJ(10)(11), Kim DW(12)(13)(14)(15).\n\nAuthor information:\n(1)Department of Anatomy and Cell Biology, Chungnam National University College \nof Medicine, Daejeon, Republic of Korea.\n(2)Brain Research Institute, Chungnam National University College of Medicine, \nDaejeon, Republic of Korea.\n(3)Department of Medical Science, Chungnam National University College of \nMedicine, Daejeon, Republic of Korea.\n(4)Department o",
      "strength": "medium"
    },
    {
      "pmid": "41135104",
      "year": "2025",
      "claim": "Microglial Replacement Reverses Age-Associated Epigenetic Modifications Despite Accelerating Epigenetic Age.",
      "source": "Aging Dis",
      "abstract": "1. Aging Dis. 2025 Oct 22. doi: 10.14336/AD.2025.1066. Online ahead of print.\n\nMicroglial Replacement Reverses Age-Associated Epigenetic Modifications Despite \nAccelerating Epigenetic Age.\n\nArbaizar-Rovirosa M(1)(2), Pérez RF(3), Peñarroya A(4)(5)(6)(7), Gallizioli \nM(1), Fraga MF(8)(4)(5)(9)(10), Planas AM(1)(2).\n\nAuthor information:\n(1)Cerebrovascular Research Laboratory, Instituto de Investigaciones.\n(2)Biomédicas de Barcelona (IIBB), Consejo Superior de Investigaciones \nCientíficas (CSIC), Barcelona, Spain. Institut d'Investigacions Biomèdiques \nAugust Pi i Sunyer (IDIBAPS), Barcelona, Spain.\n(3)Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, \nUniversidad Complutense de Madrid, Madrid, Spain.\n(4)Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investi",
      "strength": "medium"
    },
    {
      "pmid": "23493481",
      "year": "2013",
      "claim": "Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation.",
      "source": "Front Cell Neurosci",
      "abstract": "1. Front Cell Neurosci. 2013 Mar 13;7:22. doi: 10.3389/fncel.2013.00022. \neCollection 2013.\n\nMicroglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation.\n\nWong WT(1).\n\nAuthor information:\n(1)Unit on Neuron-Glia Interactions in Retinal Disease, National Eye Institute, \nNational Institutes of Health Bethesda, MD, USA.\n\nNeurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and \nage-related macular degeneration (AMD), share two characteristics in common: (1) \na disease prevalence that increases markedly with advancing age, and (2) \nneuroinflammatory changes in which microglia, the primary resident immune cell \nof the CNS, feature prominently. These characteristics have led to the \nhypothesis that pathogenic mechanisms underlying age-related neurodegenerati",
      "strength": "medium"
    }
  ],
  "market_price": 0.765
}